BV in combination with Rituximab and CHP has shown promising activity as a first-line regimen for CD30+ DLBCL, including PMBCL and grey-zone lymphoma, with an impressive ORR of 100% (86% CR) in a phase I/II trial [112]. The gene discussed is TNFRSF8; the disease is diffuse large B-cell lymphoma.